Back to Search Start Over

Integrated analysis of programmed cell death ligand 1 expression reveals increased levels in high-grade glioma.

Authors :
Hölzl, Dorothee
Hutarew, Georg
Zellinger, Barbara
Schlicker, Hans U.
Schwartz, Christoph
Winkler, Peter A.
Sotlar, Karl
Kraus, Theo F. J.
Source :
Journal of Cancer Research & Clinical Oncology. Aug2021, Vol. 147 Issue 8, p2271-2280. 10p.
Publication Year :
2021

Abstract

Purpose: Gliomas are the most frequent primary brain tumors of adults. Despite intensive research, there are still no targeted therapies available. Here, we performed an integrated analysis of glioma and programmed cell death ligand 1 (PD-L1) in 90 samples including 58 glioma and 32 control brain tissues. Methods: To identify PD-L1 expression in glioma, we performed immunohistochemical analysis of PD-L1 tumor proportion score (TPS) using the clinically valid PD-L1 22C3 antibody on 90 samples including controls and WHO grade I–IV gliomas. Results: We found that PD-L1 is highly expressed in a subfraction of glioma cells. Analysis of PD-L1 levels in different glioma subtypes revealed a strong intertumoral variation of PD-L1 protein. Furthermore, we correlated PD-L1 expression with molecular glioma hallmarks such as MGMT-promoter methylation, IDH1/2 mutations, TERT promoter mutations and LOH1p/19q. Conclusion: In summary, we found that PD-L1 is highly expressed in a subfraction of glioma, indicating PD-L1 as a potential new marker in glioma assessment opening up novel therapeutic approaches. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
01715216
Volume :
147
Issue :
8
Database :
Academic Search Index
Journal :
Journal of Cancer Research & Clinical Oncology
Publication Type :
Academic Journal
Accession number :
151103751
Full Text :
https://doi.org/10.1007/s00432-021-03656-w